Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Bladder Cancer

Free Subscription 20.05.2024 2 Actas Urol Esp (Engl Ed) 1 Am J Clin Exp Urol 1 Asian J Surg 1 bioRxiv 1 BJUI Compass 1 Cancer Res 1 Cancer Sci 1 Cancers (Basel) 2 Clin Cancer Res 1 Curr Opin Urol 1 Curr Pharm Biotechnol 1 Discov Oncol 1 EBioMedicine 3 Eur Urol 4 Eur Urol Oncol 1 FEBS Lett 1 Free Radic Biol Med 1 Front Oncol 1 Indian J Surg Oncol 3 Int J Mol Sci 1 Int J Neurosci 2 Int J Surg 1 Int J Urol 1 Int Urol Nephrol 1 J Clin Med 1 J Med Invest 1 J Natl Compr Canc Netw 1 Lab Chip 1 Lancet Oncol 2 Medicine (Baltimore) 1 Microbiome 2 Minerva Urol Nephrol 1 Mol Biotechnol 1 Mol Med Rep 1 Mol Oncol 1 Scand J Urol 1 Ther Adv Med Oncol 1 Urol Int 1 Urol J 3 Urol Oncol 1 Urologia 1 World J Urol 1 Zhong Nan Da Xue Xue Bao Yi Xue Ban

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Actas Urol Esp (Engl Ed)

1. OTERO-MURIEL IJ, Jimenez Giraldo S, Garcia-Perdomo HA
   The association between the human papillomavirus (HPV) and the diagnosis of bladder cancer: systematic review and meta-analysis.
   Actas Urol Esp (Engl Ed). 2024 May 9:S2173-5786(24)00062.
   PubMed         Abstract available
   
   
2. CANO VELASCO J, Artero Fullana S, Polanco Pujol L, Lafuente Puentedura A, et al
   Use of Bladder Epicheck(R) in the follow-up of high-risk non-muscle-invasive Bladder cancer: A systematic literature review.
   Actas Urol Esp (Engl Ed). 2024 May 10:S2173-5786(24)00064.
   PubMed         Abstract available
   
   

   
   Am J Clin Exp Urol

3. GRIFFIN RL, Shuman L, Yamashita H, Wu Q, et al
   The transcription factor sex-determining region Y-box 2 (SOX2) in bladder cancer.
   Am J Clin Exp Urol. 2024;12:88-99.
   PubMed         Abstract available
   
   

   
   Asian J Surg

4. CHI J, Jiang X, Liu Q, Cui Y, et al
   Elevated expression of SRRM3 in bladder cancer predicts poor prognosis and is associated with immune infiltration.
   Asian J Surg. 2024 May 9:S1015-9584(24)00869.
   PubMed        
   
   

   
   bioRxiv

5. FARKAS AM, Tran MA, Youssef D, Balan S, et al
   Natural Killer Cell Dysfunction In Human Bladder Cancer Is Caused By Tissue-Specific Suppression of SLAMF6 Signaling.
   bioRxiv [Preprint]. 2024 May 3:2024.04.30.591366. doi: 10.1101/2024.04.30.591366
   PubMed         Abstract available
   
   

   
   BJUI Compass

6. GUO L, Cid A, Cucci J, Kunkel B, et al
   Acu-URO17 is a highly sensitive and specific bladder cancer biomarker.
   BJUI Compass. 2024;5:497-501.
   PubMed         Abstract available
   
   

   
   Cancer Res

7. JONES RT, Scholtes M, Goodspeed A, Akbarzadeh M, et al
   NPEPPS Is a Druggable Driver of Platinum Resistance.
   Cancer Res. 2024;84:1699-1718.
   PubMed         Abstract available
   
   

   
   Cancer Sci

8. WOO HK, Park J, Kim KH, Ku JY, et al
   Alix-normalized exosomal programmed death-ligand 1 analysis in urine enables precision monitoring of urothelial cancer.
   Cancer Sci. 2024;115:1602-1610.
   PubMed         Abstract available
   
   

   
   Cancers (Basel)

9. SLUSARCZYK A, Garbas K, Pustula P, Zapala L, et al
   Assessing the Predictive Accuracy of EORTC, CUETO and EAU Risk Stratification Models for High-Grade Recurrence and Progression after Bacillus Calmette-Guerin Therapy in Non-Muscle-Invasive Bladder Cancer.
   Cancers (Basel). 2024;16:1684.
   PubMed         Abstract available
   
   

   
   Clin Cancer Res

10. BALASOORIYA ER, Wu Q, Ellis H, Zhen Y, et al
    The Irreversible FGFR Inhibitor KIN-3248 Overcomes FGFR2 Kinase Domain Mutations.
    Clin Cancer Res. 2024;30:2181-2192.
    PubMed         Abstract available
    
    
11. MAGUIRE WF, Lee D, Weinstock C, Gao X, et al
    FDA Approval Summary: Enfortumab Vedotin plus Pembrolizumab for Cisplatin-Ineligible Locally Advanced or Metastatic Urothelial Carcinoma.
    Clin Cancer Res. 2024;30:2011-2016.
    PubMed         Abstract available
    
    

    
    Curr Opin Urol

12. OBIREDDY SR, Lai WF
    Advances in preclinical approaches for intravesical therapy of bladder cancer.
    Curr Opin Urol. 2024 May 17. doi: 10.1097/MOU.0000000000001186.
    PubMed         Abstract available
    
    

    
    Curr Pharm Biotechnol

13. QIAO X, Xue R, Li S, Li J, et al
    Expression of LASS2 Can be Regulated by Dihydroartemisinin to Regulate Cisplatin Chemosensitivity in Bladder Cancer Cells.
    Curr Pharm Biotechnol. 2024 May 16. doi: 10.2174/0113892010305651240514100129.
    PubMed         Abstract available
    
    

    
    Discov Oncol

14. TUO Z, Lin Y, Zhang Y, Gao L, et al
    Prognostic significance and immune landscape of a cell cycle progression-related risk model in bladder cancer.
    Discov Oncol. 2024;15:160.
    PubMed         Abstract available
    
    

    
    EBioMedicine

15. LIU L, Xu L, Wu D, Zhu Y, et al
    Impact of tumour stroma-immune interactions on survival prognosis and response to neoadjuvant chemotherapy in bladder cancer.
    EBioMedicine. 2024;104:105152.
    PubMed         Abstract available
    
    

    
    Eur Urol

16. ABSOLOM K, Rogers Z, Catto JWF, Bottomley S, et al
    Decision Regret Regarding Treatment Choices 1 Year After a New Diagnosis of Bladder Cancer.
    Eur Urol. 2024 May 11:S0302-2838(24)02346-7. doi: 10.1016/j.eururo.2024.
    PubMed        
    
    
17. TILGENER C, Bedke J
    Re: Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma.
    Eur Urol. 2024;85:591-592.
    PubMed        
    
    
18. ROSENBERG JE, Mamtani R, Sonpavde GP, Loriot Y, et al
    Health-related Quality of Life in Patients with Previously Treated Advanced Urothelial Carcinoma from EV-301: A Phase 3 Trial of Enfortumab Vedotin Versus Chemotherapy.
    Eur Urol. 2024;85:574-585.
    PubMed         Abstract available
    
    

    
    Eur Urol Oncol

19. BENJAMIN DJ, Rezazadeh Kalebasty A, Prasad V
    The Overall Survival Benefit in EV-302: Is Enfortumab Vedotin plus Pembrolizumab the New Frontline Standard of Care for Metastatic Urothelial Carcinoma?
    Eur Urol Oncol. 2024;7:313-315.
    PubMed         Abstract available
    
    
20. SAAL J, Grunwald V, Bald T, Ritter M, et al
    On-treatment Modified Glasgow Prognostic Score Provides Predictive Information Complementary to Radiological Staging in Metastatic Urothelial Carcinoma on Immunotherapy.
    Eur Urol Oncol. 2024;7:328-331.
    PubMed         Abstract available
    
    
21. MONTORSI F, Rosiello G, Gandaglia G, Salonia A, et al
    Re: David D'Andrea, Francesco Soria, Rodolfo Hurle, et al. En Bloc Versus Conventional Resection of Primary Bladder Tumor (eBLOC): A Prospective, Multicenter, Open-label, Phase 3 Randomized Controlled Trial. Eur Urol Oncol. In press. https://doi.org/1
    Eur Urol Oncol. 2024;7:636.
    PubMed        
    
    
22. GUTMANN M, Ertl IE, Herek P, Vician P, et al
    Clofarabine Has a Superior Therapeutic Window as compared to Gemcitabine in Preclinical Bladder Cancer Models.
    Eur Urol Oncol. 2024 May 15:S2588-9311(24)00115.
    PubMed         Abstract available
    
    

    
    FEBS Lett

23. 
    Retraction: Wang C, Chen Z, Ge Q, Hu J, Li F, Hu J, Xu H, Ye Z, Li LC (2014) Up-regulation of p21(WAF1/CIP1) by miRNAs and its implications in bladder cancer cells. FEBS Letters 588, 4654-4664. https://doi.org/10.1016/j.febslet.2014.10.037.
    FEBS Lett. 2024 May 15. doi: 10.1002/1873-3468.14892.
    PubMed         Abstract available
    
    

    
    Free Radic Biol Med

24. NAKAYAMA S, Yoda E, Yamashita S, Takamatsu Y, et al
    Knockdown of iPLA(2)gamma enhances cisplatin-induced apoptosis by increasing ROS-dependent peroxidation of mitochondrial phospholipids in bladder cancer cells.
    Free Radic Biol Med. 2024;220:301-311.
    PubMed         Abstract available
    
    

    
    Front Oncol

25. QIAN L, Zhang Y, Chen H, Pang Y, et al
    The clinical effect of gratitude extension-construction theory nursing program on bladder cancer patients with fear of cancer recurrence.
    Front Oncol. 2024;14:1364702.
    PubMed         Abstract available
    
    

    
    Indian J Surg Oncol

26. GINIL KUMAR P, Gideon M, Ravi Chandran K, Pullara SK, et al
    Our Experience of OSAKA Regimen (Bladder Preservation) in Patients with Advanced Bladder Cancer.
    Indian J Surg Oncol. 2024;15:264-267.
    PubMed         Abstract available
    
    

    
    Int J Mol Sci

27. TYAGI P, Hafron J, Kaufman J, Chancellor M, et al
    Enhancing Therapeutic Efficacy and Safety of Immune Checkpoint Inhibition for Bladder Cancer: A Comparative Analysis of Injectable vs. Intravesical Administration.
    Int J Mol Sci. 2024;25:4945.
    PubMed         Abstract available
    
    
28. STURM S, Niegisch G, Windolf J, Suschek CV, et al
    Exposure of Bladder Cancer Cells to Blue Light (lambda = 453 nm) in the Presence of Riboflavin Synergistically Enhances the Cytotoxic Efficiency of Gemcitabine.
    Int J Mol Sci. 2024;25:4868.
    PubMed         Abstract available
    
    
29. DRACHNERIS J, Morkunas M, Fabijonavicius M, Cekauskas A, et al
    Spatial Distribution of Macrophage and Lymphocyte Subtypes within Tumor Microenvironment to Predict Recurrence of Non-Muscle-Invasive Papillary Urothelial Carcinoma after BCG Immunotherapy.
    Int J Mol Sci. 2024;25:4776.
    PubMed         Abstract available
    
    

    
    Int J Neurosci

30. ZHENG W, Zhang P, Yao C, Tao Y, et al
    The clinical significance of PD-1 expression in patients with bladder cancer without lymph node metastasis: a comparative study with drained lymph nodes and tumor tissues.
    Int J Neurosci. 2024 May 14:1-17. doi: 10.1080/00207454.2024.2356152.
    PubMed         Abstract available
    
    

    
    Int J Surg

31. LI X, Huang J, Ji P
    Comment on 'Robot-assisted radical cystectomy with intracorporeal urinary diversion: an updated systematic review and meta-analysis of its differential effect on effectiveness and safety'.
    Int J Surg. 2024;110:3114-3115.
    PubMed        
    
    
32. LI J, Kong Z, Qi Y, Wang W, et al
    Single-cell and bulk RNA-sequence identified fibroblasts signature and CD8+ T-cell - fibroblast subtype predicting prognosis and immune therapeutic response of bladder cancer, based on machine-learning bioinformatics retrospective study.
    Int J Surg. 2024 May 17. doi: 10.1097/JS9.0000000000001516.
    PubMed         Abstract available
    
    

    
    Int J Urol

33. HAYAKAWA N, Kikuchi E
    Editorial Comment on "Effectiveness of adjuvant chemotherapy for patients who undergo radical cystectomy without neoadjuvant chemotherapy: A retrospective cohort study of 115 advanced bladder cancer patients with pathological lymph node classification
    Int J Urol. 2024 May 16. doi: 10.1111/iju.15495.
    PubMed        
    
    

    
    Int Urol Nephrol

34. DAVID J, Pathak RA
    Editorial comment for "Surgeon-administered regional nerve blocks during radical cystectomy: a feasibility study".
    Int Urol Nephrol. 2024;56:1937-1938.
    PubMed        
    
    

    
    J Clin Med

35. CONTIERI R, Pichler R, Del Giudice F, Marcq G, et al
    Variation in Follow-Up after Radical Cystectomy for Bladder Cancer-An Inventory Roundtable and Literature Review.
    J Clin Med. 2024;13:2637.
    PubMed         Abstract available
    
    

    
    J Med Invest

36. TEMIRCAN Z
    Investigation of Knowledge, Attitudes, and Healthy Lifestyle Behaviors on Bladder Cancer in Turkey.
    J Med Invest. 2024;71.
    PubMed         Abstract available
    
    

    
    J Natl Compr Canc Netw

37. FLAIG TW, Spiess PE, Abern M, Agarwal N, et al
    Bladder Cancer, Version 3.2024.
    J Natl Compr Canc Netw. 2024;22:216-225.
    PubMed         Abstract available
    
    

    
    Lab Chip

38. XIN L, Xiao X, Xiao W, Peng R, et al
    Screening for urothelial carcinoma cells in urine based on digital holographic flow cytometry through machine learning and deep learning methods.
    Lab Chip. 2024;24:2736-2746.
    PubMed         Abstract available
    
    

    
    Lancet Oncol

39. NECCHI A, Roumiguie M, Kamat AM, Shore ND, et al
    Pembrolizumab monotherapy for high-risk non-muscle-invasive bladder cancer without carcinoma in situ and unresponsive to BCG (KEYNOTE-057): a single-arm, multicentre, phase 2 trial.
    Lancet Oncol. 2024 May 10:S1470-2045(24)00178.
    PubMed         Abstract available
    
    

    
    Medicine (Baltimore)

40. EKICI M, Demir E, Aydin C, Caglayan MS, et al
    Can the use of antithrombotic drugs be a predictive factor in the early diagnosis of bladder cancer?: A single-center analysis.
    Medicine (Baltimore). 2024;103:e38228.
    PubMed         Abstract available
    
    
41. QIU Y, Jiang Z, Zhang J
    Causal effects of BMI, waist circumference, and body fat percentage on the risk of bladder cancer: A Mendelian randomization study.
    Medicine (Baltimore). 2024;103:e38231.
    PubMed         Abstract available
    
    

    
    Microbiome

42. THEN CK, Paillas S, Moomin A, Misheva MD, et al
    Dietary fibre supplementation enhances radiotherapy tumour control and alleviates intestinal radiation toxicity.
    Microbiome. 2024;12:89.
    PubMed         Abstract available
    
    

    
    Minerva Urol Nephrol

43. ZAWKY M, Elsayed A, Awadallah A, Abdelhalim A, et al
    The impact of purified protein derivative prior to intravesical bacillus Calmette-Guerin for the treatment of patients with non-muscle invasive bladder cancer.
    Minerva Urol Nephrol. 2024 May 17. doi: 10.23736/S2724-6051.23.05515.
    PubMed         Abstract available
    
    
44. PALERMO M, D'Elia C, Trenti E, Comploj E, et al
    Prospective evaluation of the RT-PCR based urinary marker Bladder Epicheck(R) as a diagnostic tool in upper urinary tract tumor.
    Minerva Urol Nephrol. 2024;76:195-202.
    PubMed         Abstract available
    
    

    
    Mol Biotechnol

45. WANG Z, Zhang J, Luo L, Zhang C, et al
    Nucleoporin 93 Regulates Cancer Cell Growth and Stemness in Bladder Cancer via Wnt/beta-Catenin Signaling.
    Mol Biotechnol. 2024 May 14. doi: 10.1007/s12033-024-01184.
    PubMed         Abstract available
    
    

    
    Mol Med Rep

46. LIAO G, Chen F, Zhong J, Jiang X, et al
    [Retracted] MicroRNA?539 inhibits the proliferation and invasion of bladder cancer cells by regulating IGF?1R.
    Mol Med Rep. 2024;30:116.
    PubMed         Abstract available
    
    

    
    Mol Oncol

47. PAN YC, Chu PY, Lin CC, Hsieh CY, et al
    Glutathione S-transferase omega class 1 (GSTO1)-associated large extracellular vesicles are involved in tumor-associated macrophage-mediated cisplatin resistance in bladder cancer.
    Mol Oncol. 2024 May 15. doi: 10.1002/1878-0261.13659.
    PubMed         Abstract available
    
    

    
    Scand J Urol

48. SCILIPOTI P, Liedberg F, Garmo H, Wilberg Orrason A, et al
    Risk of prostate cancer death in men diagnosed with prostate cancer at cystoprostat-ectomy. A nationwide population-based study.
    Scand J Urol. 2024;59:98-103.
    PubMed         Abstract available
    
    

    
    Ther Adv Med Oncol

49. LI DX, Yu QX, Wu RC, Wang J, et al
    Efficiency of bladder-sparing strategies for bladder cancer: an umbrella review.
    Ther Adv Med Oncol. 2024;16:17588359241249068.
    PubMed         Abstract available
    
    

    
    Urol Int

50. CHO HJ, Chung HS, Hwang EC, Jung SI, et al
    Music from noise-canceling headphones is beneficial against anxiety in male bladder cancer patients undergoing follow-up cystoscopy: A prospective randomized trial.
    Urol Int. 2024 May 10. doi: 10.1159/000539312.
    PubMed         Abstract available
    
    

    
    Urol J

51. TANG Z, Can L, Xuan S, Chen L, et al
    Unveiling the Etiology of Urological Tumors: A Systematic Review of Mendelian Randomization Applications in Renal Cell Carcinoma, Bladder Cancer, and Prostate Cancer.
    Urol J. 2024 May 11. doi: 10.22037/uj.v21i.7970.
    PubMed         Abstract available
    
    

    
    Urol Oncol

52. MAHLOW J, Gupta S
    Pathology focused review of morphologic subtypes and molecular variants of urothelial carcinoma with an emphasis on clinical/treatment relevance.
    Urol Oncol. 2024;42:193-202.
    PubMed         Abstract available
    
    
53. OLAH C, Kubik A, Matrai P, Engh MA, et al
    Estimation of the incidence of urachal cancer: A systematic review and meta-analysis of registry-based studies.
    Urol Oncol. 2024;42:221.
    PubMed         Abstract available
    
    
54. WANG Y, Song Y, Peng Y, Han S, et al
    Effects of androgen suppression therapy on the incidence and prognosis of bladder cancer: An updated systematic review and meta-analysis.
    Urol Oncol. 2024 May 9:S1078-1439(24)00431-9. doi: 10.1016/j.urolonc.2024.
    PubMed         Abstract available
    
    

    
    Urologia

55. SERRETTA V
    BCG and bladder cancer. Forty-eight years after Morales report.
    Urologia. 2024 May 17:3915603241252909. doi: 10.1177/03915603241252909.
    PubMed         Abstract available
    
    

    
    World J Urol

56. BEN-DAVID R, Tillu N, Alerasool P, Bieber C, et al
    Induction and maintenance of sequential intravesical gemcitabine/docetaxel for intermediate and high-risk non-muscle invasive bladder cancer with different dosage protocols.
    World J Urol. 2024;42:315.
    PubMed         Abstract available
    
    

    
    Zhong Nan Da Xue Xue Bao Yi Xue Ban

57. LI R, Ning Y, Yuan Y, Yang X, et al
    Molecular mechanisms of ferroptosis and its effects on bladder cancer.
    Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2024;49:286-295.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Bladder Cancer is free of charge.